Disclosed is a method for determining whether a dog is anextensive metabolizer or a poor metabolizer in the rate of drugmetabolism, by preparing a DNA sample from a dog, anddetermining a base corresponding to a base at position 1117 ofa canine CYP1A2 gene (i.e., at position 87 of exon 4).According to the method, a CYP1A2 gene diagnosis of dogs(particularly beagles) used in a pharmacological effect test ora toxicity test can be rapidly carried out prior to the test,and thus the dogs can be easily divided into a group having anormal metabolic ability (an extensive metabolizer group) and agroup having a low metabolic ability (a poor metabolizergroup).
展开▼
